/
Oncology
Locally Advanced or Metastatic Solid Tumors
46
Pipeline Programs↗
44
Active Trials↗
48
Companies Involved↗
Locally Advanced or Metastatic Solid Tumors is a moderately active landscape with 46 programs across 48 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., AbbVie, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 125
Phase 218
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
36 of 40 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 93% of 46 pipeline programs.
Analysis
Trial Status
143
clinical trials
Completed69 · 48%
Recruiting30 · 21%
Terminated17 · 12%
Active, not recruiting8 · 6%
Unknown status8 · 6%
Not yet recruiting6 · 4%
Other5 · 3%
Clinical Trials
Trial Activity
143 trials
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)